All articles by Staff Writer
AOP Health: Completed study strengthens clinical development program for ropeginterferon alpha 2b (BESREMi®) in polycythaemia vera
With the publication of the final results from the LOW-PV study in the New England Journal of Medicine Evidence conducted by Fondazione per la Ricerca dell’Ospedale di Bergamo (FROM) under the leadership of Professor Tiziano Barbui, AOP Health announces an important advancement reinforcing its clinical development program for ropeginterferon alpha-2b (BESREMi®) in polycythaemia vera (PV), a rare blood cancer. The academic LOW-PV study supported and funded by AOP Health and public organizations in Italy complements a series of trials performed by AOP Health over more than 10 years to achieve marketing authorization in Europe and the Middle East. With these clinical studies, including PEGINVERA, PROUD-PV, and CONTINUATION-PV, AOP Health opened a new area of treatment options for patients suffering from PV. A further study (PEN-PV) was performed to develop a pen for self-injection allowing ease of self-administration, exact dosing and minimal waste of the medical product. AOP Health’s comprehensive development program in PV is considered by many key opinion leaders as the most significant development in the field of PV treatment in the past 30 years.
Baxter Launches Progressa+ Next Gen ICU Bed to Help Address Complex Critical Care Needs
Developed in collaboration with nurses and therapists to help ease the burden on critical care teams Supports care teams as they address pulmonary, skin and mobility challenges common in the ICU environment Launches in U.S. with global expansion planned to begin later this year
Danicopan as add-on to ULTOMIRIS® or SOLIRIS® improved hemoglobin levels and maintained disease control in patients with PNH experiencing signs or symptoms of clinically significant extravascular hemolysis
Results from ALPHA Phase III trial demonstrated statistically significant increase compared to placebo in mean hemoglobin from baseline to week 12 All key secondary endpoints met statistical superiority, showing danicopan reduced fatigue and anemia as well as the need for transfusions
Coloplast announces agreement to acquire Kerecis and raises long-term growth expectations
Today Coloplast announced the following statement. We’re excited to join the Coloplast family and have their support in becoming the world leader in tissue regeneration. We’re committed to making a difference while turning waste into value, in the most sustainable way.
Revvity Tests Included in UK’s Updated NICE Diagnostic Guidance for Pre-Eclampsia DG-49
Two Revvity CE marked tests are recommended in latest version of NICE guidance “PLGF-based testing to help diagnose suspected preterm pre-eclampsia” for UK healthcare providers
Bruker Announces New D6 PHASERTM Benchtop X-Ray Diffraction (XRD) Platform for Materials Analysis and Advanced Research
Bruker Corporation (Nasdaq: BRKR), the global leader in X-ray diffraction, today announces the new D6 PHASERTM X-Ray Diffraction (XRD) system. The D6 PHASER is a new benchtop XRD platform designed with the analytical flexibility typically only available in larger, floor-standing systems. Unlike conventional, more limited benchtop XRD instruments, the D6 PHASER enables analytical methods that go beyond powder diffraction. With its wide range of capabilities, the D6 PHASER will enable more XRD applications for new markets and user communities.
Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, participated in today’s U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee’s (VRBPAC) meeting, which resulted in a unanimous vote recommending updating the current COVID vaccine composition to a monovalent XBB-lineage.
Flen Health Receives 1.7 Million Grant from VLAIO for Groundbreaking Research on Recombinant Engineering of Wound-Healing Enzymes
Flen Health is proud to announce that it has been awarded a 1.7 million research and development grant by the Flanders Innovation & Entrepreneurship (VLAIO – for short) to leverage further its leading expertise in biological wound treatment research and development. The award represents the funding at approximately 60% of a 3.0 million project.
Thermo Fisher Scientific Introduces Tumoroid Culture Medium to Accelerate Development of Novel Cancer Therapies
Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the Gibco™ OncoPro™ Tumoroid Culture Medium Kit*, the first commercially available culture medium specifically developed for the expansion of patient-derived tumoroids, or cancer organoids, from multiple cancer indications.
Wound dressing FibDex® to be clinically tested for treatment of superficial dermal burns
UPM Biomedicals’ innovative wound dressing FibDex is undergoing a clinical investigation of performance and safety in patients with superficial dermal burns. The clinical investigation will be conducted by the Burn Centre of Uppsala University Hospital, Sweden, and is estimated to be completed in the beginning of the year 2025.